Economics of Innovation
Optimal innovation balances willingness and ability to pay with the benefits of future R&D. Our wide-ranging programme aims to promote innovation in health care, increase our understanding of its value, and encourage R&D. New models of innovation should streamline development, reduce costs, and speed patient benefit.
Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
1 December 2018
The proliferation of health data in our ever more digitalised world of health care creates opportunities for better research around – and delivery of – pharmaceutical…
2017 OHE Annual Report to the Charity Commission
1 November 2018
This is OHE’s report to the Charity Commission for England and Wales for the year 2017, OHE’s first since becoming a registered charity in December 2016.…
The Impact of New Medicines in the NHS: 70 Years of Innovation
1 August 2018
In 2018, the NHS turns 70. This OHE Consulting Report demonstrates the contribution and impact of medicines to the health economy in the UK throughout the…
Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS
1 August 2018
This OHE Consulting Report reviews “Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS.” The project was funded by the ABPI. For the year…
Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
1 July 2018
The current system of a single price per medicine means that, for multi-indication medicines, the relationship between price and “value” can vary substantially. In this OHE…
Establishing a Reasonable Price for an Orphan Drug
1 July 2018
The high cost of drugs for rare diseases (‘orphan drugs’) has generated considerable debate. While there is debate in the economic literature over whether a premium…
R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C
1 July 2018
Using a multidisciplinary methodological approach combining a theoretical economic framework with uptake/market share analyses by country and interviews, this OHE research concludes that: (i) IP incentives…
The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
5 January 2018
The notion that the price of a medicine should be linked in some way to value it generates for patients and the health system is generally…
A Critique of the Paper “The Estimated Costs of Production and Potential Prices for the World Health Organization Essential Medicines List”
1 May 2018
This OHE Consulting Report reviews “Estimated costs of production and potential prices of medicines for the World Health Organization Essential Medicines List” (Hill et al., 2018)…